溶瘤麻疹病毒的临床试验：现状与未来展望。
Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.
机构信息
MD Anderson Cancer Center, Division of Cancer Medicine, 1400 Holcombe Blvd, Unit 0463, Houston, TX 77030, USA.
Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA.
出版信息
Curr Cancer Drug Targets. 2018;18(2):177-187. doi: 10.2174/1568009617666170222125035.
Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.
减毒 Edmonston 谱系麻疹病毒（MV-Edm）疫苗株可以优先感染和溶解多种癌细胞。溶瘤 MV-Edm 衍生物经过基因工程改造，可表达人癌胚抗原（MV-CEA 病毒）或人钠碘同向转运体（MV-NIS 病毒），目前正在临床试验中针对卵巢癌、胶质母细胞瘤、多发性骨髓瘤、间皮瘤、头颈部癌、乳腺癌和恶性外周神经鞘瘤进行测试。这篇综述描述了促进 MV-Edm 株临床转化的基础和临床前数据，并总结了迄今为止该溶瘤平台的临床结果。此外，我们还讨论了最新的临床相关 MV-Edm 载体发展和未来转化步骤的创新策略。
Zotero 插件